A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults
- Conditions
- Epstein-Barr Virus Infection
- Interventions
- Biological: Placebo
- Registration Number
- NCT05164094
- Lead Sponsor
- ModernaTX, Inc.
- Brief Summary
The main objective of Part A of this trial is to evaluate the safety and reactogenicity of mRNA-1189 in 18- to 30-year-old healthy adults, the main objective of Part B is to evaluate the safety and reactogenicity of mRNA-1189 in 12- to \<18-year-old healthy EBV-seronegative adolescents, and the main objective of Part C is to evaluate the safety and reactogenicity of mRNA-1189 in 10- to 21-year-old healthy adolescents and adults.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 867
- According to the assessment of the investigator, is in good general health and can comply with study procedures.
Part A: Healthy adult from 18 to 30 years of age (inclusive) at the time of consent (Screening Visit, Day 0).
Part B:
Healthy baseline EBV-seronegative adolescents from 12 to <18 years of age at the time of consent (Screening Visit, Day 0).
Part C:
Healthy adolescents and adults from 10 to 21 years of age (inclusive) at the time of consent (Screening Visit, Day 0).
- Has had significant exposure to someone with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or COVID-19 in the past 14 days prior to the screening visit, if the participant has not been fully vaccinated against COVID-19 at least 14 days prior to the screening visit.
- Has symptomatic acute or chronic illness requiring ongoing medical or surgical care, to include changes in medication in the past 2 months indicating that chronic illness/disease is not stable (at the discretion of the investigator).
- Significant, progressive, unstable or uncontrolled clinical condition, including any condition that may affect participant safety, assessment of study endpoints, assessment of immune response, or adherence to study procedures per investigator judgement.
- Has a history of myocarditis, and/or pericarditis.
- Has received or plans to receive any licensed or authorized vaccine, to include COVID-19 vaccines, ≤28 days prior to the first injection (Day 1) or plans to receive a licensed vaccine within 28 days before or after any study vaccine injection, with the exception of licensed influenza vaccines, which may be received more than 14 days before or after any study vaccine injection.
Note: Other inclusion and exclusion criteria may apply.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Part C: mRNA-1189 Dose Level 2 mRNA-1189 Participants will receive 3 IM injections of mRNA-1189 at Dose Level 2 on Days 1, 57, and 169. Part C: mRNA-1189 Dose Level 3 mRNA-1189 Participants will receive 3 IM injections of mRNA-1189 at Dose Level 3 on Days 1, 57, and 169. Part C: Placebo Placebo Participants will receive 3 IM injection of study drug-matching placebo on Days 1, 57, and 169. Part B: Placebo Placebo Participants will receive 3 IM injection of study drug-matching placebo on Days 1, 57, and 169. Part C: mRNA-1189 Dose Level 1 mRNA-1189 Participants will receive 3 IM injections of mRNA-1189 at Dose Level 1 on Days 1, 57, and 169. Part A: mRNA-1189 Dose Level 2 mRNA-1189 Participants will receive 3 intramuscular (IM) injections of mRNA-1189 at Dose Level 2 on Days 1, 57, and 169. Part A: mRNA-1189 Dose Level 3 mRNA-1189 Participants will receive 3 IM injections of mRNA-1189 at Dose Level 3 on Days 1, 57, and 169. Part A: mRNA-1189 Dose Level 4 mRNA-1189 Participants will receive 3 IM injections of mRNA-1189 at Dose Level 4 on Days 1, 57, and 169. Part A: Placebo Placebo Participants will receive 3 IM injection of study drug-matching placebo on Days 1, 57, and 169. Part B: mRNA-1189 Dose Level 1 mRNA-1189 Participants will receive 3 IM injections of mRNA-1189 at Dose Level 1 on Days 1, 57, and 169. Part B: mRNA-1189 Dose Level 2 mRNA-1189 Participants will receive 3 IM injections of mRNA-1189 at Dose Level 2 on Days 1, 57, and 169. Part B: mRNA-1189 Dose Level 3 mRNA-1189 Participants will receive 3 IM injections of mRNA-1189 at Dose Level 3 on Days 1, 57, and 169. Part B: mRNA-1189 Dose Level 4 mRNA-1189 Participants will receive 3 IM injections of mRNA-1189 at Dose Level 4 on Days 1, 57, and 169.
- Primary Outcome Measures
Name Time Method Number of Participants with Unsolicited Adverse Events (AEs) Up to Day 197 (28-day follow-up after vaccination) Number of Participants with SAEs, MAAEs, Any AEs Leading to Withdrawal From Study/Discontinuation of Study Vaccine and AEs of Special Interest (AESIs) Day 1 to end of study (EOS) (Day 505) Number of Participants with Laboratory Abnormalities Up to Day 176 (7-day follow-up after vaccination) Number of Participants with Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs) Up to Day 176 (7-day follow-up after vaccination)
- Secondary Outcome Measures
Name Time Method Geometric Mean Titer (GMT) of B-Cell Neutralizing Antibody (nAb) and/or Antigen-Specific Binding Antibody (bAb) Days 1, 85, and 197 Geometric Mean Fold Rise (GMFR) of B-Cell nAb and Antigen-Specific bAb Days 1, 85, and 197 Number of Participants With Seroconversion of B-Cell nAbs and/or Antigen-Specific bAbs Days 1, 85, and 197 The number of initially EBV-negative participants with seroconversion from below the lower limit of quantification (LLOQ) to above the LLOQ for EBV-specific (vaccine antigen) binding and nAbs responses and the initially EBV-positive participants with \> 2-, 3-, and 4-fold increases in serum binding or nAb titers from baseline (if above LLOQ) will be analyzed.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (56)
Medical Affiliated Research Institute
🇺🇸Huntsville, Alabama, United States
Alliance for Multispecialty Research, LLC
🇺🇸Norfolk, Virginia, United States
Smart Cures Clinical Research
🇺🇸Anaheim, California, United States
Benchmark Research - Colton - HyperCore - PPDS
🇺🇸Colton, California, United States
Fomat Medical Research
🇺🇸Oxnard, California, United States
Center For Clinical Trials LLC -Paramount
🇺🇸Paramount, California, United States
Artemis Institute For Clinical Research LLC - Riverside - Headlands - PPDS
🇺🇸Riverside, California, United States
Peninsula Research Associates - Headlands Research - PPDS
🇺🇸Rolling Hills, California, United States
Velocity Clinical Research - Banning - PPDS
🇺🇸San Bernardino, California, United States
Acclaim Clinical Research
🇺🇸San Diego, California, United States
Scroll for more (46 remaining)Medical Affiliated Research Institute🇺🇸Huntsville, Alabama, United States